127 related articles for article (PubMed ID: 11975272)
1. Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
Thomas S
Nurs Stand; 2000 Jul 19-25; 14(44):20. PubMed ID: 11975272
[No Abstract] [Full Text] [Related]
2. Bad decision NICE.
Ellis SJ
Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
[No Abstract] [Full Text] [Related]
3. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
Bryant J; Clegg A; Milne R
BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
[No Abstract] [Full Text] [Related]
4. A cost-utility analysis of interferon beta for multiple sclerosis.
Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
[No Abstract] [Full Text] [Related]
5. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
6. [Interferon-beta in multiple sclerosis--who is going to be treated?].
Aarli JA
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
[No Abstract] [Full Text] [Related]
7. Funding of drug treatment of multiple sclerosis should not be delayed.
Paty DW
BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
[No Abstract] [Full Text] [Related]
8. Multiple sclerosis drug prompts rationing fears.
Dyer O
BMJ; 1995 Oct; 311(7011):969. PubMed ID: 7580631
[No Abstract] [Full Text] [Related]
9. Beta interferon and multiple sclerosis: why the fuss?
Mumford CJ
QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
[No Abstract] [Full Text] [Related]
10. A purchaser perspective of managing new drugs: interferon beta as a case study.
Walley T; Barton S
BMJ; 1995 Sep; 311(7008):796-9. PubMed ID: 7580445
[TBL] [Abstract][Full Text] [Related]
11. Shortcomings in pharmacy benefit forecasting--interferon beta products.
Rich SJ; Meyer C
J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
[No Abstract] [Full Text] [Related]
12. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
13. [A short history of beta-interferon therapy of multiple sclerosis].
Stock G; Horowski R
Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
[TBL] [Abstract][Full Text] [Related]
14. Beta interferon, NICE, and rationing.
Kernick D
Br J Gen Pract; 2002 Sep; 52(482):784-5. PubMed ID: 12236297
[No Abstract] [Full Text] [Related]
15. Health department to fund interferon beta despite institute's ruling.
Mayor S
BMJ; 2001 Nov; 323(7321):1087. PubMed ID: 11701567
[No Abstract] [Full Text] [Related]
16. Funding medicines for people with multiple sclerosis.
Taylor D
BMJ; 2001 Dec; 323(7326):1379-80. PubMed ID: 11744549
[No Abstract] [Full Text] [Related]
17. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
Detournay B
Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
Nuijten MJ; Hutton J
Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis risk sharing scheme: a costly failure.
Raftery J
BMJ; 2010 Jun; 340():c1672. PubMed ID: 20522654
[No Abstract] [Full Text] [Related]
20. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
